Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jcph.1693 http://scihub22266oqcxt.onion/10.1002/jcph.1693 32557541!7323169!32557541     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Pharmacol 2020 ; 60 (9): 1131-1146 Nephropedia Template TP {{tp|p=32557541|t=2020. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome |pdf=|usr=}}{{32557541}} gab.com Text A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome JO: J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32557541 #FOAvip Currently, the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19. Twit Text FOAVip A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome ????J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32557541 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32557541 #FOAvip English Wikipedia <ref>{{Cite pmid|32557541}}</ref> A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome #MMPMID32557541 Khiali S; Khani E; Entezari-Maleki T J Clin Pharmacol 2020[Sep]; 60 (9): 1131-1146 PMID32557541show ga Currently, the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19. |*COVID-19 Drug Treatment[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage/pharmacology[MESH] |COVID-19/complications[MESH] |Cytokine Release Syndrome/drug therapy/virology[MESH] |Humans[MESH] |Interleukin-6/immunology[MESH]A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Di(epmc).pdf DeepDyve Pubget Overpricing